Home Pharma

Pharma

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender

CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to...

Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase...

American College of Cardiology, Novartis collaborate to optimize HF care

ACC, Novo Nordisk Partner to Improve Cardiovascular Disease Management in Patients...

Arrowhead Appoints Oye Olukotun to Board of Directors as the company...

Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular...

Novartis new analysis shows high consistency in lowering LDL-C in individual...

New Insights into How COVID-19 Causes Heart Damage

New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage...

ETNA-AF-Europe Registry Data on LIXIANA (edoxaban) Highlights Important Clinical Considerations for...

12 3...9 Page 1 of 9

MOST POPULAR

Penumbra Announces FDA Clearance of RED 62 Perfusion Catheter

Miami Cardiac & Vascular Institute Receives Certification of Excellence in Transcatheter...

CentraCare First in World to Use 4D Hologram Technology to Successfully...

Robocath and Rennes University Hospital launch co-development research program into treatment...

Load more

HOT NEWS